Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) VP Alvin D. Howard sold 3,375 shares of the business’s stock in a transaction dated Monday, November 19th. The stock was sold at an average price of $3.90, for a total transaction of $13,162.50. Following the sale, the vice president now directly owns 38,414 shares in the company, valued at approximately $149,814.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

FOMX traded up $0.11 during midday trading on Tuesday, reaching $3.80. 14,305 shares of the company’s stock were exchanged, compared to its average volume of 797,963. The stock has a market cap of $212.25 million, a P/E ratio of -2.16 and a beta of 2.10. Foamix Pharmaceuticals Ltd has a 1-year low of $3.65 and a 1-year high of $7.60.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). The business had revenue of $0.87 million for the quarter, compared to analyst estimates of $1.10 million. Foamix Pharmaceuticals had a negative return on equity of 118.29% and a negative net margin of 2,049.92%. Research analysts predict that Foamix Pharmaceuticals Ltd will post -1.65 earnings per share for the current fiscal year.

FOMX has been the topic of a number of research analyst reports. HC Wainwright set a $11.00 price objective on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 8th. Cantor Fitzgerald initiated coverage on shares of Foamix Pharmaceuticals in a report on Thursday, October 11th. They set an “overweight” rating on the stock. Zacks Investment Research raised shares of Foamix Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a report on Wednesday, September 19th. BidaskClub downgraded shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 9th. Finally, Cowen set a $30.00 target price on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, November 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. Foamix Pharmaceuticals currently has an average rating of “Hold” and an average price target of $13.69.

Several large investors have recently bought and sold shares of the company. ARK Investment Management LLC raised its position in shares of Foamix Pharmaceuticals by 17.7% in the second quarter. ARK Investment Management LLC now owns 106,243 shares of the specialty pharmaceutical company’s stock valued at $532,000 after buying an additional 15,980 shares during the last quarter. Millennium Management LLC raised its position in shares of Foamix Pharmaceuticals by 2.6% in the first quarter. Millennium Management LLC now owns 763,296 shares of the specialty pharmaceutical company’s stock valued at $3,916,000 after buying an additional 19,628 shares during the last quarter. Trexquant Investment LP raised its position in shares of Foamix Pharmaceuticals by 205.6% in the third quarter. Trexquant Investment LP now owns 34,950 shares of the specialty pharmaceutical company’s stock valued at $200,000 after buying an additional 23,515 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Foamix Pharmaceuticals in the third quarter valued at approximately $166,000. Finally, Wells Fargo & Company MN raised its position in shares of Foamix Pharmaceuticals by 31.7% in the third quarter. Wells Fargo & Company MN now owns 132,900 shares of the specialty pharmaceutical company’s stock valued at $761,000 after buying an additional 32,013 shares during the last quarter. 49.63% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Alvin D. Howard Sells 3,375 Shares of Foamix Pharmaceuticals Ltd (FOMX) Stock” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/11/20/alvin-d-howard-sells-3375-shares-of-foamix-pharmaceuticals-ltd-fomx-stock.html.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.

Featured Story: Float

Insider Buying and Selling by Quarter for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.